As allogeneic cell therapies advance through clinical development, Human Leukocyte Antigen (HLA) matching has become one of the most consequential technical decisions facing therapy developers. HLA compatibility between donor cells and the recipient’s immune system directly impacts whether transplanted cells engraft, function, or trigger potentially life-threatening immune reactions. While HLA compatibility remains critical, matching standards continue to shift as clinical protocols and therapeutic technologies rapidly advance.
What Is HLA and Why Does It Matter?
Human Leukocyte Antigens are proteins expressed on the surface of most human cells. They function as the immune system’s identification system, enabling it to distinguish self from non-self. When donor cells carry HLA molecules that differ from the recipient’s, the recipient’s immune system may recognize those cells as foreign and mount an immune response, leading to graft rejection. Conversely, if donor immune cells (particularly T cells) recognize the recipient’s tissues as foreign, they can attack the recipient’s organs, a condition known as graft-versus-host disease (GvHD).
The HLA system is encoded by the most polymorphic gene region in the human genome. According to the most recent IMGT/HLA database update, over 23,900 HLA alleles have been described to date, with new variants continuously being identified through next-generation sequencing. This extreme genetic diversity is what makes matching so challenging, and so important.
HLA Typing Methods: From Serology to NGS
The accuracy and resolution of HLA typing have improved dramatically over the past three decades, with each technological generation enabling more precise matching predictions.
Serological typing was the mainstream method before the 1990s, using antibody-based recognition to identify HLA proteins. While functional, it lacked the sensitivity to detect small amino acid differences that can provoke significant immune responses.
PCR-based methods including sequence-specific primer (SSP) and sequence-specific oligonucleotide probe (SSOP) techniques provide four-digit resolution and remain widely used. Sanger sequencing-based typing (SBT) improved resolution to six-to-eight digits and became the gold standard for clinical applications.
Next-generation sequencing (NGS) represents the current state of the art. NGS enables full gene coverage including introns and untranslated regions, accurate allele phasing, and high-throughput processing. This technology has been instrumental in the discovery of thousands of new HLA alleles and provides the resolution needed for precise donor-recipient matching in cell therapy applications.
OrganaBio runs high-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP on every donor in our 1,000+ qualified, recallable pool. KIR genotyping available for NK programs. Both RUO and cGMP grades sourced from the same donor pool under one quality system.
Browse the leukopak + immune cell catalog →HLA Matching Requirements by Therapy Type
One of the most important things for cell therapy developers to understand is that HLA matching requirements are not uniform. They vary significantly depending on the type of therapy being developed.
Hematopoietic Stem Cell Transplantation
HSC transplantation has the most stringent HLA matching requirements in cell therapy. The current consensus recommends matching at HLA-A, B, and C (Class I) and HLA-DRB1 (Class II), with additional consideration for HLA-DPB1 and DQB1. Recipients receiving better matched grafts have superior survival outcomes, and incompatibility at even a single locus increases the risk of both GvHD and graft rejection. An HLA-identical sibling remains the optimal first choice for HSC transplant.
CAR-T Cell Therapy
Allogeneic CAR-T development faces a dual challenge: preventing the donor T cells from causing GvHD while ensuring the recipient’s immune system does not reject the infused cells. Published data shows that HLA-matched allogeneic CAR-T cells demonstrate higher complete response rates compared to HLA-haploidentical approaches. These studies show induced transient or no reduction in peripheral blood leukemia cells with poor CAR-T expansion, suggesting immune-mediated rejection.
This has driven two parallel strategies: sourcing from HLA-matched donors and using gene editing to create “universal” CAR-T cells.
CAR-NK Cell Therapy
NK cell-based therapies represent a significant departure from T cell approaches with respect to HLA matching. Allogeneic CAR-NK cells, particularly those derived from cord blood, can be administered without full HLA matching. Clinical trial data has confirmed that despite substantial HLA disparity between donors and recipients, no GvHD was observed.[7] This characteristic makes cord blood-derived NK cells particularly attractive for off-the-shelf applications, as it eliminates the need to manufacture a unique product matched to each patient’s HLA profile.
Mesenchymal Stromal Cells (MSCs)
MSC-based therapies have the most permissive HLA matching requirements among major cell therapy modalities. Undifferentiated MSCs express HLA class I but not class II molecules; the International Society for Cell Therapy definition requires 2% or less HLA-DR expression.[6] This low immunogenicity means the vast majority of allogeneic MSC clinical trials do not include HLA matching as a requirement, and clinical outcomes data confirms that MSC treatment is well tolerated regardless of HLA match status between donor and recipient.
HLA Banking for Off-the-Shelf Therapies
The development of off-the-shelf allogeneic therapies has driven significant interest in creating HLA-typed cell banks: collections of donor cells characterized for their HLA profiles that can be matched to patient populations without requiring individual donor selection for each patient.
Two primary strategies are emerging. The first is the HLA matching approach: building banks of cells from donors with common HLA haplotypes that can serve significant portions of the target population. Research on iPSC haplobanks has shown that using the 180 most frequent HLA haplotypes across 18 populations achieves coverage ranging from 54.6% (in genetically diverse populations like India) to 81.7% (in more homogeneous populations like Sweden), with a global mean of 68.4%.[2]
The second is the HLA engineering approach: using gene editing technologies such as CRISPR/Cas9 to modify HLA genes in donor cells, creating hypo-immunogenic cells that evade both T cell and NK cell-mediated rejection. Published research in Nature Communications (2025) has demonstrated that CRISPR disruption of B2M and CIITA combined with insertion of an HLA-E-B2M fusion gene generates cells that retain functional stability and suppressive capabilities while evading immune detection, potentially enabling truly universal donor cells.[3]
OrganaBio launched cGMP CD34+ HSC manufacturing from cord blood in 2024 via GaiaGift, our wholly owned, FDA-registered perinatal subsidiary. NGS HLA typing supports allogeneic donor matching for off-the-shelf programs.
See cord blood CD34+ HSC product →Current Challenges in HLA Matching
Despite technological advances, several challenges continue to complicate HLA matching for cell therapy applications.
Population diversity gaps. Non-Caucasian ethnicities remain underrepresented in donor registries worldwide. Depending on ethnic origin, 1–5% of patients do not have a single potentially matched donor in existing registries. Genetically diverse populations have more haplotypes at lower individual frequencies, making it harder to find matches through standard banking approaches.
Rare haplotype coverage. While the likelihood of finding a 10/10-matched unrelated donor reaches 75% for patients of European descent, it drops to approximately 16% for African American patients, even after searching registries of millions of donors.[4] For patients with uncommon HLA combinations, search success rates can be significantly lower still, even after months of searching through large registries.
Cost and infrastructure. Building and maintaining comprehensive HLA-typed cell banks require significant investment in NGS-based typing, donor recruitment across diverse populations, and manufacturing infrastructure to support multiple HLA-characterized product lines.
Data quality variability. Historical HLA typing data varies in resolution and completeness. As programs move toward high-resolution NGS-based typing, reconciling legacy data with current standards requires specialized bioinformatics expertise.
Selecting HLA Typing Service and Cell Sourcing Partner
For therapy developers, the choice of cell sourcing partner has direct implications for HLA matching capabilities and program success. Key considerations include the resolution and methodology of HLA typing offered (high-resolution NGS-based typing across HLA-A, B, C, DR, DQ, and DP loci is the current standard), the size and diversity of the donor pool, the ability to select donors based on specific HLA alleles and additional parameters such as CMV status and blood type, and whether the partner can provide both research-grade and clinical-grade products with consistent HLA characterization throughout the program lifecycle.
Access to recallable donors is particularly valuable for programs that require longitudinal collections or need to return to a specific donor as the program advances. And comprehensive documentation, including Certificates of Analysis with HLA genotype data, infectious disease testing results, and full traceability, is essential for IND submissions and regulatory compliance.
The field of HLA matching for cell therapy is advancing rapidly, with new technologies, banking strategies, and engineering approaches expanding what is possible. For developers of allogeneic therapies, staying current with these developments and partnering with suppliers that offer comprehensive HLA typing and characterized donor materials is a strategic imperative.
Schedule a 30-minute cell sourcing call. We will walk through HLA-typed donor access, recallable pool depth, NGS typing CoA, and how OrganaBio fits your program timeline.
References
[1] Barker DJ, et al. “The IPD-IMGT/HLA Database: recent developments in sequence submission.” Nucleic Acids Research. 2026;54:D1152–D1158.
[2] Maiers M, et al. “Harnessing global HLA data for enhanced patient matching in iPSC haplobanks.” Cytotherapy. 2025;27(3):300–306.
[3] Nature Communications. “HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy.” 2025.
[4] Gragert L, et al. “HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry.” New England Journal of Medicine, 2014;371(4):339–348. doi:10.1056/NEJMsa1311707
[5] Dominici M, et al. “Minimal criteria for defining multipotent mesenchymal stromal cells.” Cytotherapy. 2006;8(4):315–317.
[6] Liu E, et al. “Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.” N Engl J Med. 2020;382(6):545–553.
